Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo’s Revenue Up 16.9% in April-December on Buoyant Mainstays
February 1, 2023
- Sumitomo Suffers 18.5 Billion Yen Net Loss in April-December on Kynmobi Woes
February 1, 2023
- Ono’s 9-Month Revenue Climbs 25% on Robust Opdivo and Forxiga Sales
February 1, 2023
- Jardiance Filed in Japan for Chronic Kidney Disease: BI/Lilly
February 1, 2023
- Daiichi Sankyo Taps CFO Okuzawa as New President, Set to Continue ADC Drive
February 1, 2023
- Boehringer Ingelheim in AMD Collab with Jichi Medical University
January 31, 2023
- BMS, Kyoto University Join Hands to Deliver Innovative Drugs
January 31, 2023
- Teijin Pharma’s Osteoporosis Med Ostabalo Now Available in Japan
January 31, 2023
- AnGes to Start Japan PII for NF-κB Decoy Oligo for Lower Back Pain
January 31, 2023
- Rexulti Filed for Major Depressive Disorder in Japan: Otsuka
January 31, 2023
- Shionogi Logs Record Profits as Xocova Nets 100 Billion Yen from Govt Purchase: April-December
January 31, 2023
- UCB Files Bimzelx for Label Expansion in Psoriatic Arthritis and More
January 31, 2023
- Lecanemab Earns Priority Review in Japan, Eisai Aims for Approval by Year-End
January 31, 2023
- Takeda to Transfer MS Med Copaxone to Teva JV, 1st Patented Drug under 2020 Pact
January 30, 2023
- Estimated 21,528 Patients Given Xocova as of Jan. 22: Shionogi
January 30, 2023
- Lecanemab Application Accepted for Review in Europe; FY2023 Approval Eyed
January 30, 2023
- NanoCarrier to Shift Biz Model to mRNA Out-Licensing, Joins Forces with Axcelead
January 27, 2023
- Torii Acquires Japan Rights for Nogra Pharma’s Acne Drug
January 27, 2023
- Enhertu Wins EU Approval for HER2 Low Breast Cancer
January 27, 2023
- Shipments of All 6 Argatroban Products Suspended or Restricted in Japan
January 26, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…